Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 316
- Registration Number
- NCT02871869
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi, Xinjiang, China
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT02846428
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT02760953
Reduced Chemotherapy in Low Risk DLBCL
- Conditions
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 290
- Registration Number
- NCT02752815
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2021-09-23
- Target Recruit Count
- 40
- Registration Number
- NCT02742051
- Locations
- 🇨🇳
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China
Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2017-10-24
- Target Recruit Count
- 40
- Registration Number
- NCT02694224
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 174
- Registration Number
- NCT02685059
- Locations
- 🇩🇪
Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus, Frankfurt, Hessen, Germany
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 780
- Registration Number
- NCT02682693
- Locations
- 🇩🇪
Charité Campus Mitte, Berlin, Germany
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 256
- Registration Number
- NCT02631499
- Locations
- 🇨🇳
Nantong Tumor Hospital, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 200
- Registration Number
- NCT02627248
- Locations
- 🇨🇳
Qilu hospital of Shandong University, Ji'nan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.